Biotechnology Company Receives New Price Target From Investment Bank

In the dynamic world of biotechnology, companies come and go. However, some manage to capture the attention of investors and industry experts due to their innovative approaches and promising pipelines. One such company is IN8bio (NASDAQ: $INAB), which has recently been initiated with a 'Buy' rating by investment bank Laidlaw & Co., along with an encouraging price target of $7.5. $In8bio(INAB.US)$